Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study
- PMID: 9165384
- DOI: 10.1016/s0165-0327(96)01427-9
Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study
Abstract
In a randomised multicentre study, the prophylactic efficacy of lithium and carbamazepine was compared in 144 patients with bipolar disorder (74 vs. 70 patients; observation period: 2.5 years; lithium serum level: 0.63 +/- 0.12 mmol/l, carbamazepine dose: 621 +/- 186 mg/day). Hospitalisations, recurrences, need of psychotropic comedication and adverse effects prompting discontinuation were defined as treatment failures. Survival analyses regarding hospitalisations and recurrences showed no statistically significant differences between both drugs. Results were distinctly in favour of lithium, considering recurrences combined with comedication (P = 0.041) and/or adverse effects (P = 0.007). Whereas adverse effects prompting discontinuation were more frequent under carbamazepine (9 vs. 4, ns), lithium patients reported more often slight/moderate side effects (61% vs. 21% after 2.5 years; P = 0.0006). In completers, recurrences occurred in 28% (lithium) vs. 47% (carbamazepine) of the patients (P = 0.06). Lithium seems to be superior to carbamazepine in maintenance treatment of bipolar disorder, in particular when applying broader outcome criteria including psychotropic comedication and severe side effects.
Similar articles
-
Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study.Eur Arch Psychiatry Clin Neurosci. 1997;247(1):42-50. doi: 10.1007/BF02916252. Eur Arch Psychiatry Clin Neurosci. 1997. PMID: 9088805 Clinical Trial.
-
The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder.Int Clin Psychopharmacol. 1999 Sep;14(5):277-81. Int Clin Psychopharmacol. 1999. PMID: 10529070 Clinical Trial.
-
Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified.Int Clin Psychopharmacol. 1999 Sep;14(5):283-5. Int Clin Psychopharmacol. 1999. PMID: 10529071 Clinical Trial.
-
Rational polypharmacy in the bipolar affective disorders.Epilepsy Res Suppl. 1996;11:153-80. Epilepsy Res Suppl. 1996. PMID: 9294735 Review.
-
Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder.J Clin Psychiatry. 2008;69 Suppl 5:9-15. J Clin Psychiatry. 2008. PMID: 19265635 Review.
Cited by
-
Drug-induced diabetes insipidus: incidence, prevention and management.Drug Saf. 1999 Dec;21(6):449-56. doi: 10.2165/00002018-199921060-00002. Drug Saf. 1999. PMID: 10612269 Review.
-
Clinical course and need for hospital admission after lithium discontinuation in patients with bipolar disorder type I or II: mirror-image study based on the LiSIE retrospective cohort.BJPsych Open. 2019 Nov 22;5(6):e101. doi: 10.1192/bjo.2019.83. BJPsych Open. 2019. PMID: 31753046 Free PMC article.
-
Chronic clozapine reduces rat brain arachidonic acid metabolism by reducing plasma arachidonic acid availability.J Neurochem. 2013 Feb;124(3):376-87. doi: 10.1111/jnc.12078. Epub 2012 Dec 6. J Neurochem. 2013. PMID: 23121637 Free PMC article.
-
Efficacy of Carbamazepine and Its Derivatives in the Treatment of Bipolar Disorder.Medicina (Kaunas). 2021 Apr 30;57(5):433. doi: 10.3390/medicina57050433. Medicina (Kaunas). 2021. PMID: 33946323 Free PMC article. Review.
-
Epidemiology, diagnosis and management of mixed mania.CNS Drugs. 2007;21(8):611-26. doi: 10.2165/00023210-200721080-00001. CNS Drugs. 2007. PMID: 17630815 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous